Influence of different factors (duration of disease, gender, education, patients' history, job and age) in metformin response in type 2 diabetes mellitus patient
Abstract
OBJECTIVE: Aim: This study aims to evaluate how various factors affect various aspects of glycemic control in individuals with type 2 diabetes who are undergoing metformin treatment.
PATIENTS AND METHODS: Materials and Methods: A cross-sectional study involved 150 participants who met specific criteria, including being aged between 30 and 70, having a type 2 diabetes diagnosis, and using 1000 mg of metformin as the monotherapy for at least three months. Collected data encompassed various measures, such as levels of glycated hemoglobin (HbA1c), fasting blood glucose concentrations, fasting serum insulin levels, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), and insulin sensitivity.
RESULTS: Results: Our research reveals that when it comes to factors such as several socio-demographic variables, there is no statistically significant difference (p-value ≥ 0.05) between patients who exhibit a positive response to metformin and those who do not. Nevertheless, distinctions were noted in patients' previous history and the duration of their illness, which did influence their treatment response.
CONCLUSION: Conclusions: Glycemic parameters in individuals with type 2 diabetes can be impacted by a range of factors, such as age, gender, and occupation also it's important to note that these outcomes influenced by additional variables like the adherence for medication, and the existence of diabetes-related complications.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 150 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.